Chie Emoto

Chie Emoto

UNVERIFIED PROFILE

Are you Chie Emoto?   Register this Author

Register author
Chie Emoto

Chie Emoto

Publications by authors named "Chie Emoto"

Are you Chie Emoto?   Register this Author

35Publications

419Reads

14Profile Views

Utilizing Pediatric Physiologically Based Pharmacokinetic Models to Examine Factors That Contribute to Methadone Pharmacokinetic Variability in Neonatal Abstinence Syndrome Patients.

J Clin Pharmacol 2020 Apr 9;60(4):453-465. Epub 2019 Dec 9.

Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcph.1538DOI Listing
April 2020

Next Challenge From the Variance in Individual Physiologically-Based Pharmacokinetic Model-Predicted to Observed Morphine Concentration in Critically Ill Neonates.

Clin Pharmacol Ther 2020 Feb 12;107(2):319-320. Epub 2019 Sep 12.

Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cpt.1607DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6980935PMC
February 2020

Clinical Applications of Physiologically Based Pharmacokinetic Modeling: Perspectives on the Advantages and Challenges.

Ther Drug Monit 2020 Feb;42(1):157-158

Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FTD.0000000000000714DOI Listing
February 2020

Influence of MRP3 Genetics and Hepatic Expression Ontogeny for Morphine Disposition in Neonatal and Pediatric Patients.

J Clin Pharmacol 2020 Feb 24. Epub 2020 Feb 24.

Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcph.1592DOI Listing
February 2020

Busulfan Pharmacokinetics and Precision Dosing: Are Patients with Fanconi Anemia Different?

Biol Blood Marrow Transplant 2019 Dec 18;25(12):2416-2421. Epub 2019 Jul 18.

Department of Pediatrics, Bone Marrow Transplant Service, Memorial Sloan Kettering, New York, New York; Division of Pediatric Hematology-Oncology, New York Presbyterian Hospital-Weill Cornell Medical College, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.07.014DOI Listing
December 2019

Population pharmacokinetic modelling of busulfan and the influence of body composition in paediatric Fanconi anaemia patients.

Br J Clin Pharmacol 2019 Dec 18. Epub 2019 Dec 18.

Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bcp.14202DOI Listing
December 2019

Adult and infant pharmacokinetic profiling of dihydrocodeine using physiologically based pharmacokinetic modeling.

Biopharm Drug Dispos 2019 Nov 21;40(9):350-357. Epub 2019 Nov 21.

Showa Pharmaceutical University, Machida, Tokyo, 194-8543, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/bdd.2209DOI Listing
November 2019

Evidence of a clinically significant drug-drug interaction between cannabidiol and tacrolimus.

Am J Transplant 2019 10 21;19(10):2944-2948. Epub 2019 May 21.

Division of Nephrology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.15398DOI Listing
October 2019

A Theoretical Physiologically-Based Pharmacokinetic Approach to Ascertain Covariates Explaining the Large Interpatient Variability in Tacrolimus Disposition.

CPT Pharmacometrics Syst Pharmacol 2019 05 7;8(5):273-284. Epub 2019 Mar 7.

Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/psp4.12392DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6539708PMC
May 2019

Influence of OCT1 Ontogeny and Genetic Variation on Morphine Disposition in Critically Ill Neonates: Lessons From PBPK Modeling and Clinical Study.

Clin Pharmacol Ther 2019 03 8;105(3):761-768. Epub 2018 Nov 8.

Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cpt.1249
Publisher Site
http://dx.doi.org/10.1002/cpt.1249DOI Listing
March 2019

PBPK Model of Morphine Incorporating Developmental Changes in Hepatic OCT1 and UGT2B7 Proteins to Explain the Variability in Clearances in Neonates and Small Infants.

CPT Pharmacometrics Syst Pharmacol 2018 07 19;7(7):464-473. Epub 2018 Jun 19.

Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/psp4.12306
Publisher Site
http://dx.doi.org/10.1002/psp4.12306DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6063742PMC
July 2018

Using a Vancomycin PBPK Model in Special Populations to Elucidate Case-Based Clinical PK Observations.

CPT Pharmacometrics Syst Pharmacol 2018 04 15;7(4):237-250. Epub 2018 Feb 15.

Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/psp4.12279
Publisher Site
http://dx.doi.org/10.1002/psp4.12279DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915605PMC
April 2018

Evaluation of intestinal metabolism and absorption using the Ussing chamber system equipped with intestinal tissue from rats and dogs.

Eur J Pharm Biopharm 2018 Jan 30;122:49-53. Epub 2017 Sep 30.

Bioavailability Research Project, Formulation Research Institute, Otsuka Pharmaceutical Co. Ltd., 224-18 Ebisuno Hiraishi Kawauchi-cho, Tokushima 771-0182, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejpb.2017.09.015DOI Listing
January 2018

Model-based precision dosing of sirolimus in pediatric patients with vascular anomalies.

Eur J Pharm Sci 2017 Nov 17;109S:S124-S131. Epub 2017 May 17.

Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA; Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, OH, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejps.2017.05.037DOI Listing
November 2017

Developmental pharmacokinetics of sirolimus: Implications for precision dosing in neonates and infants with complicated vascular anomalies.

Pediatr Blood Cancer 2017 Aug 16;64(8). Epub 2017 Feb 16.

Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pbc.26470DOI Listing
August 2017

Arachidonic acid with taurine enhances pulmonary absorption of macromolecules without any serious histopathological damages.

Eur J Pharm Biopharm 2017 May 13;114:22-28. Epub 2017 Jan 13.

BA Project, Formulation Research Institute, Otsuka Pharmaceutical Co. Ltd., 224-18 Ebisuno Hiraishi Kawauchi-cho, Tokushima 771-0182, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejpb.2016.12.020DOI Listing
May 2017

Pretransplant Absolute Lymphocyte Counts Impact the Pharmacokinetics of Alemtuzumab.

Biol Blood Marrow Transplant 2017 Apr 12;23(4):635-641. Epub 2017 Jan 12.

Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital, Cincinnati, Ohio; Department of Pediatrics, University of Cincinnati, Cincinnati, Ohio.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2017.01.071DOI Listing
April 2017

Developmental Changes in Hepatic Organic Cation Transporter OCT1 Protein Expression from Neonates to Children.

Drug Metab Dispos 2017 01 25;45(1):23-26. Epub 2016 Oct 25.

Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio (D.H., C.E., A.A.V., T.F); and Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, Ohio (C.E., A.A.V., T.F)

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.116.072256DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6047210PMC
January 2017

Prediction of drug intestinal absorption in human using the Ussing chamber system: A comparison of intestinal tissues from animals and humans.

Eur J Pharm Sci 2017 Jan 6;96:373-380. Epub 2016 Oct 6.

Bioavailability Research Project, Formulation Research Institute, Otsuka Pharmaceutical Co. Ltd., 224-18 Ebisuno Hiraishi Kawauchi-cho, Tokushima 771-0182, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejps.2016.10.006DOI Listing
January 2017

A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation.

Biol Blood Marrow Transplant 2016 12 21;22(12):2220-2225. Epub 2016 Sep 21.

Division of Bone Marrow Transplantation and Immune Deficiency, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2016.09.016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5683393PMC
December 2016

Risk Assessment of Drug-Drug Interactions of Calcineurin Inhibitors Affecting Sirolimus Pharmacokinetics in Renal Transplant Patients.

Ther Drug Monit 2016 10;38(5):607-13

*Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio; and †Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FTD.0000000000000314DOI Listing
October 2016

The impact of CYP3A5*3 polymorphism on sirolimus pharmacokinetics: insights from predictions with a physiologically-based pharmacokinetic model.

Br J Clin Pharmacol 2015 Dec 28;80(6):1438-46. Epub 2015 Oct 28.

Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bcp.12743DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693485PMC
December 2015

Age-dependent changes in sirolimus metabolite formation in patients with neurofibromatosis type 1.

Ther Drug Monit 2015 Jun;37(3):395-9

*Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center; †Department of Pediatrics, College of Medicine, University of Cincinnati, OH; ‡iC42 Integrated Solutions in Clinical Research and Development, University of Colorado, Aurora; §Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD; ¶Division of Oncology, The Children's Hospital of Philadelphia; ‖Department of Pediatrics, The Perelman School of Medicine, University of Pennsylvania, Philadelphia; **Division of Oncology, Cancer and Blood Disease Institute, Cincinnati Children's Hospital Medical Center; and ††Department of Pharmacology and Cell Biophysics, College of Medicine, University of Cincinnati, OH.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FTD.0000000000000130DOI Listing
June 2015

Human pharmacokinetic profiling of the dipeptidyl peptidase-IV inhibitor teneligliptin using physiologically based pharmacokinetic modeling.

Biopharm Drug Dispos 2015 Apr 28;36(3):148-62. Epub 2015 Jan 28.

Showa Pharmaceutical University, Machida, Tokyo, 194-8543, Japan; Mitsubishi Tanabe Pharma Co, Kisarazu, Chiba, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/bdd.1928DOI Listing
April 2015

Comparison of p450 enzymes between cynomolgus monkeys and humans: p450 identities, protein contents, kinetic parameters, and potential for inhibitory profiles.

Curr Drug Metab 2013 Feb;14(2):239-52

Department of Drug Metabolism, Tokushima Research Institute, Otsuka Pharmaceutical Co. Ltd., 463-10 Kagasuno, Tokushima, Japan.

View Article

Download full-text PDF

Source
February 2013

Discovery of 1-(β-amino substituted-β-alanyl)-N,N-dimethylindoline-2-carboxamides as novel nonpeptide antagonists of nociceptin/orphanin FQ receptor: efficient design, synthesis, and structure-activity relationship studies.

Eur J Med Chem 2012 Sep 25;55:228-42. Epub 2012 Jul 25.

Pfizer Global Research & Development, Nagoya Laboratories, Pfizer Japan Inc., 5-2 Taketoyo, Aichi 470-2393, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejmech.2012.07.021DOI Listing
September 2012

Characterization of intestinal and hepatic P450 enzymes in cynomolgus monkeys with typical substrates and inhibitors for human P450 enzymes.

Xenobiotica 2012 Aug;42(8):719-30

Department of Drug Metabolism, Drug Safety Research Center, Tokushima Research Institute, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/00498254.2012.656732DOI Listing
August 2012

Methodologies for investigating drug metabolism at the early drug discovery stage: prediction of hepatic drug clearance and P450 contribution.

Curr Drug Metab 2010 Oct;11(8):678-85

Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University, Machida, Tokyo 194-8543, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/138920010794233503DOI Listing
October 2010

Effects of histidine-tag on recombinant human cytochrome P450 3A5 catalytic activity in reconstitution systems.

Drug Metab Lett 2009 Dec;3(4):207-11

Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University, Machida, Tokyo 194-8583, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/187231209790218109DOI Listing
December 2009

Effects of enzyme sources on midazolam 1'-hydroxylation activity catalyzed by recombinant cytochrome P450 3A4 in combination with NADPH-cytochrome P450 reductase.

Drug Metab Lett 2008 Aug;2(3):190-2

Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University, Machida, Tokyo 194-8583, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/187231208785425737DOI Listing
August 2008

Comparison of kinetic parameters for drug oxidation rates and substrate inhibition potential mediated by cytochrome P450 3A4 and 3A5.

Curr Drug Metab 2008 Jan;9(1):20-33

Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University, Machida, Tokyo 194-8583, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/138920008783331121DOI Listing
January 2008

In vitro inhibitory effect of 1-aminobenzotriazole on drug oxidations in human liver microsomes: a comparison with SKF-525A.

Drug Metab Pharmacokinet 2005 Oct;20(5):351-7

Department of Pharmacokinetics Dynamics Metabolism, Nagoya Laboratories, Pfizer Japan Inc., Taketoyo, Aichi, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2133/dmpk.20.351DOI Listing
October 2005

In vitro inhibitory effect of 1-aminobenzotriazole on drug oxidations catalyzed by human cytochrome P450 enzymes: a comparison with SKF-525A and ketoconazole.

Drug Metab Pharmacokinet 2003 ;18(5):287-95

Department of Pharmacokinetics Dynamics Metabolism, Nagoya Laboratories, Pfizer Inc., Taketoyo, Aichi, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2133/dmpk.18.287DOI Listing
March 2005

Causative agent of vascular pain among photodegradation products of dacarbazine.

J Pharm Pharmacol 2002 Aug;54(8):1117-22

Department of Pharmacy, Shinshu University Hospital, 3-1-1 Asahi, Matsumoto, 390-8621, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1211/002235702320266280DOI Listing
August 2002